Rapamycin / Sirolimus

Rapamycin was discovered in 1972 by a research team led by Suren Sehgal at Ayerst Laboratories, isolated from a soil sample collected on Easter Island (Rapa Nui) containing the actinomycete bacterium Streptomyces hygroscopicus. Initially characterized as a potent antifungal agent, its immunosuppressive properties were recognized in the early 1980s and prompted a major medicinal chemistry program that ultimately led to FDA approval in 1999 as Rapamune (sirolimus) for the prophylaxis of organ rejection in adult patients receiving renal transplants. Subsequent clinical approvals expanded its therapeutic profile: the FDA approved sirolimus for lymphangioleiomyomatosis (LAM) in 2015, and rapalog derivatives everolimus (Afinitor, Zortress) and temsirolimus (Torisel) derived from rapamycin were approved across a spectrum of oncological indications. Rapamycin gave its name to the mechanistic Target of Rapamycin (mTOR), a serine/threonine kinase central to nutrient sensing, anabolic growth, and longevity biology; the mTOR protein was independently identified as the rapamycin target by at least three laboratories in 1994 and named FRAP, RAFT1, and RAPT1 before the consensus name mTOR was adopted. Today rapamycin occupies a unique scientific position as both an approved pharmaceutical and the single most validated pharmacological intervention for lifespan extension in animal models, driving a substantial body of translational research into its geroprotective potential in humans.

Rapamycin's mechanism is two-step and requires an intracellular adapter protein. Rapamycin enters cells and binds with picomolar affinity to FKBP12, a 12-kDa cytosolic immunophilin (peptidyl-prolyl cis-trans isomerase) named for its affinity for the structurally related immunosuppressant FK506 (tacrolimus). The resulting binary FKBP12-rapamycin complex then binds the FRB (FKBP12-Rapamycin Binding) domain of mTOR in a gain-of-function manner, forming a ternary complex that sterically and allosterically inhibits the mTORC1 kinase domain. mTORC1 is the rapamycin-sensitive complex, defined by its RPTOR (Raptor) scaffold protein and responsible for phosphorylating S6K1 and 4E-BP1 to drive protein synthesis and ribosome biogenesis. mTORC2, the second mTOR complex, is defined by its RICTOR scaffold and is acutely rapamycin-insensitive because RICTOR prevents FKBP12-rapamycin from accessing the mTOR FRB domain in the mTORC2 context; however, prolonged rapamycin exposure can inhibit mTORC2 assembly in some cell types by sequestering newly synthesized mTOR, producing AKT Ser473 hypophosphorylation that impairs insulin signaling and contributes to the glucose intolerance observed with chronic daily dosing. mTORC1 integrates four major input signals: growth factors (via PI3K-AKT-TSC2 axis), amino acids (via Rag GTPase-Ragulator complex at the lysosomal surface), energy status (via AMPK-TSC2 and AMPK-RAPTOR), and cellular stresses, functioning as a coincidence detector that licenses anabolic programs only when all inputs are favorable.

The discovery that rapamycin extends mammalian lifespan was made serendipitously in the ITP program: the drug arrived late and was not administered until mice were 600 days old, equivalent to approximately 60 human years. Despite the late start, Harrison and colleagues (Nature, 2009) observed median lifespan extension of 9 percent in males and 14 percent in females across three independent research sites, findings immediately recognized as paradigm-shifting because they demonstrated that aging itself is pharmacologically tractable in old organisms, not just in young ones. The biological plausibility of the result rests on rapamycin's documented restoration of youthful transcriptional patterns in multiple aged tissues, including reversal of cardiac gene expression signatures of aging, restoration of stem cell function in multiple tissues, and suppression of the inflammatory gene programs that drive inflammaging. Subsequent ITP experiments systematically characterized the dose-response, timing, and combination effects of rapamycin: earlier treatment start enhances the longevity signal, higher doses produce larger effects, and combinations with 17-alpha-estradiol and acarbose are additive in males. The ITP has also studied potential adverse effects of rapamycin in aging mice and found that the expected immunosuppressive and metabolic side effects are present at transplant-equivalent doses, supporting the translational argument that lower doses and intermittent schedules should be studied in humans. The PEARL trial (NCT04488601, ongoing as of 2026) is the most advanced human trial specifically designed to test rapamycin for geroprotection in community-dwelling older adults, and the Dog Aging Project (DAP) is conducting a parallel trial in companion dogs as an intermediate mammalian model with similar lifespan and disease spectrum to humans.

Rapamycin's pharmacokinetics are dominated by its extensive intestinal and hepatic CYP3A4 metabolism and P-gp efflux, yielding an oral bioavailability of approximately 15 percent that varies substantially with food, formulation, and co-medications. The approximately 62-hour half-life means once-weekly dosing maintains meaningful mTORC1 suppression for several days after each dose, with recovery before the next dose; this pharmacokinetic profile is the biological rationale for intermittent longevity protocols. Drug interactions are clinically significant: CYP3A4 inhibitors (ketoconazole, diltiazem, clarithromycin, voriconazole, grapefruit) increase rapamycin exposure between 1.6-fold and 10-fold, while CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) reduce it by 50 to 82 percent; these interactions necessitate therapeutic drug monitoring at transplant doses and careful co-medication review at any dose level. The off-label longevity dosing landscape is currently empirical: regimens of 1 to 6 mg per week are used by an estimated tens of thousands of people globally based on open-label case series, clinician protocols, and the ITP animal data, without randomized controlled trial evidence specifically establishing safety and efficacy for aging in humans. The mechanistic rationale for intermittent versus continuous dosing is substantiated by Lamming et al. (Science, 2012), who demonstrated that daily rapamycin in mice causes insulin resistance and glucose intolerance through mTORC2 disruption while every-other-day dosing largely preserved metabolic function, though the specific weekly intermittent protocol used in human longevity practice has not been directly compared to continuous dosing in a controlled trial. Monitoring parameters for individuals using rapamycin off-label include complete blood count, comprehensive metabolic panel including fasting glucose and HbA1c, fasting lipid panel, and periodic renal function, assessed at baseline and at 3 to 6 month intervals.

Mechanism of Action

FKBP12 Binding and mTORC1 Allosteric Inhibition

Rapamycin is a macrolide lactone with a unique two-step mechanism of intracellular action that fundamentally distinguishes it from ATP-competitive kinase inhibitors. After entering cells through passive diffusion facilitated by its high lipophilicity, rapamycin binds with picomolar affinity (Kd approximately 0.2 nM) to FKBP12 (FK506-binding protein 12 kDa, encoded by FKBP1A), a ubiquitous cytosolic peptidyl-prolyl cis-trans isomerase. The FKBP12-rapamycin binary complex does not inhibit FKBP12’s enzymatic isomerase activity per se; instead, the complex gains a new binding surface complementary to the FRB (FKBP12-Rapamycin Binding) domain of mTOR, engaging it in a ternary inhibitory complex. The ternary complex formation allosterically inhibits mTORC1 kinase activity by perturbing substrate access to the kinase active site, specifically preventing the correct docking of S6K1 and 4E-BP1 substrates rather than occluding the ATP-binding site. This mechanism allows rapamycin to selectively inhibit mTORC1 over mTORC2, because RICTOR adopts a conformation within mTORC2 that sterically occludes the FRB domain, preventing FKBP12-rapamycin from forming the ternary complex in the mTORC2 context. FK506 (tacrolimus), which also binds FKBP12 with picomolar affinity, does not inhibit mTOR despite its structural similarity to rapamycin, because its FKBP12-FK506 complex presents a different surface that lacks the complementarity for the mTOR FRB domain; the distinction between rapamycin and FK506 pharmacology was pivotal in establishing that the FKBP12-rapamycin binding surface, not FKBP12 isomerase inhibition, is the pharmacophore.

mTORC1 Substrate Suppression and Growth Arrest

Once mTORC1 is inhibited by the FKBP12-rapamycin-mTOR ternary complex, the consequences cascade through two primary substrate pathways. S6K1 (RPS6KB1), the first substrate, normally phosphorylated at Thr389 by mTORC1, is dephosphorylated, eliminating its activating phosphorylation and reducing downstream phosphorylation of ribosomal protein S6, eIF4B, PDCD4, and eEF2K; the net effect is reduced ribosome biogenesis, reduced cap-dependent mRNA translation initiation, and reduced translation elongation efficiency, collectively suppressing protein synthesis globally, with particular selectivity for TOP (terminal oligopyrimidine) mRNAs encoding ribosomal proteins and translation factors. 4E-BP1 (EIF4EBP1), the second major mTORC1 substrate, is normally multisite phosphorylated by mTORC1 at Thr37, Thr46, Ser65, and Thr70, which prevents it from binding and sequestering the 5’-cap-binding eIF4E translation initiation factor; rapamycin-induced 4E-BP1 dephosphorylation allows 4E-BP1 to reassociate with eIF4E and block cap-dependent translation initiation, with disproportionate impact on mRNAs with highly structured 5’ UTRs encoding pro-growth and pro-survival proteins including cyclin D1, c-Myc, HIF-1alpha, VEGF, and ornithine decarboxylase. The differential sensitivity of S6K1 and 4E-BP1 to rapamycin is important: S6K1 phosphorylation is highly rapamycin-sensitive, while 4E-BP1 hyperphosphorylation at the later sites is partially rapamycin-resistant in some cell types and requires higher doses or catalytic mTOR inhibitors (mTOR kinase inhibitors, TORKi) for full suppression; this differential sensitivity partially explains why rapalogs produce cytostatic rather than cytotoxic effects in most cancer types.

Autophagy Induction via ULK1 and TFEB Activation

mTORC1 inhibition activates autophagy through two complementary mechanisms that together produce a rapid and sustained increase in autophagic flux. First, mTORC1 normally maintains ULK1 in an inactive state through phosphorylation at Ser757 (in the spacer domain), which prevents AMPK from phosphorylating the activating Ser555 site and blocks ULK1 complex assembly; rapamycin removes this inhibitory phosphorylation within minutes, enabling ULK1 to autophosphorylate, assemble the ULK1-ATG13-FIP200-ATG101 complex, and initiate phagophore nucleation at the ER-mitochondria contact site. The phagophore elongation that follows requires BECN1 (Beclin-1) activation by ULK1 phosphorylation of AMBRA1, which releases Beclin-1 from BCL-2/BCL-XL inhibition and activates the VPS34-PI3K-III lipid kinase complex to produce PI3P (phosphatidylinositol 3-phosphate) on nascent phagophore membranes. Second, mTORC1 normally phosphorylates TFEB (transcription factor EB) at Ser142 and Ser211, retaining it in the cytoplasm through 14-3-3 protein binding; mTORC1 inhibition allows TFEB dephosphorylation by phosphatase PP2A and nuclear translocation, where TFEB binds the CLEAR (Coordinated Lysosomal Expression and Regulation) motif in the promoters of more than 400 autophagy and lysosomal genes, expanding the lysosomal compartment and autophagic capacity to match the increased autophagic input. Together, ULK1-mediated autophagy initiation and TFEB-mediated lysosomal biogenesis produce a coordinated amplification of autophagic flux that clears long-lived proteins, damaged organelles (through mitophagy, ER-phagy, and ribophagy), and misfolded protein aggregates associated with neurodegeneration and aging.

Chronic mTORC2 Inhibition and the Dosing Frequency Problem

mTORC2, defined by its RICTOR scaffold, is acutely rapamycin-insensitive because RICTOR sterically prevents FKBP12-rapamycin from accessing the mTOR FRB domain in that complex. However, Sarbassov and colleagues (Molecular Cell, 2006) demonstrated that prolonged rapamycin treatment in multiple cell lines gradually reduces mTORC2 activity by a different mechanism: newly synthesized mTOR protein is captured by FKBP12-rapamycin before it can be incorporated into RICTOR-containing mTORC2 complexes, progressively depleting the pool of mTOR available for mTORC2 assembly. The result is reduced RICTOR-mTOR interaction, reduced mTORC2 kinase activity, and reduced AKT Ser473 phosphorylation, which partially uncouples AKT from full activation and impairs downstream phosphorylation of FoxO transcription factors, BAD, and GSK-3. Lamming and colleagues (Science, 2012) confirmed in mice that chronic daily rapamycin produces glucose intolerance and insulin resistance through this mTORC2-mediated AKT Ser473 deficiency, a phenotype that mimics partial liver-specific AKT knockout and is not observed with intermittent dosing schedules that allow mTORC2 to recover between doses. The cell-type dependence of mTORC2 rapamycin sensitivity is important: hepatocytes, adipocytes, and certain immune cells appear more susceptible to mTORC2 inhibition by prolonged rapamycin than other cell types, explaining why the insulin resistance phenotype is metabolically dominant. For longevity dosing, intermittent administration (weekly or less frequent) is hypothesized to maintain therapeutic mTORC1 inhibition during the pharmacological active window while allowing mTORC2 recovery in the latter part of the dosing interval, based on the half-life argument that drug levels fall substantially by day 4 to 5 after a single weekly dose.

Senomorphic SASP Suppression

Cellular senescence, the stable growth arrest driven by p16-INK4a, p21, and DNA damage response activation, paradoxically drives tissue aging through the SASP, a pro-inflammatory secretome that includes IL-6, IL-8, IL-1alpha, MMP3, MMP9, and PAI-1. mTORC1 is required for SASP translation even after growth arrest is established, because the SASP mRNAs encoding pro-inflammatory cytokines contain structural features (5’ TOP elements, internal ribosome entry sites) that make their translation particularly dependent on mTORC1-driven ribosome activity. Rapamycin suppresses SASP secretion in senescent cells without reversing the growth arrest itself, reducing the paracrine and endocrine inflammatory signals that damage neighboring tissue, impair stem cell function, and drive inflammaging. This senomorphic effect (modulating senescence secretome rather than eliminating senescent cells) is mechanistically complementary to senolytics (dasatinib, quercetin, navitoclax) that physically eliminate CDKN2A-expressing cells; combining senomorphics and senolytics may produce additive reductions in senescence burden and SASP. In aged mice, rapamycin treatment reduces circulating IL-6 and other SASP components and is associated with reduced perigonadal adipose tissue inflammation, consistent with a systemic senomorphic effect contributing to the longevity phenotype.

Immunomodulation and T-cell Subset Selectivity

Rapamycin’s immunosuppressive activity exploits the differential mTORC1 dependence of distinct T-cell subsets. Effector T-cells (CD4 Th1, Th2, Th17, and CD8 cytotoxic) rely heavily on mTORC1-driven glycolysis and metabolic reprogramming to support rapid proliferation after antigen stimulation, making them highly sensitive to rapamycin-mediated growth arrest. Regulatory T-cells (Tregs, marked by FOXP3) are more dependent on oxidative phosphorylation and fatty acid oxidation and are less sensitive to mTORC1 inhibition for their lineage maintenance and suppressive function; at sub-maximal rapamycin concentrations, effector T-cells are preferentially suppressed while Tregs are relatively expanded, a feature exploited in transplant tolerance protocols and investigated for autoimmunity treatment. This T-cell subset selectivity also shapes the immune rejuvenation biology in aging: aged immune systems are characterized by accumulation of exhausted effector T-cells and reduced Treg function; rapamycin reverses both deficits through mTORC1-dependent mechanisms, explaining the vaccine response improvements observed by Mannick and colleagues and the reduction in inflammatory markers in aged rapamycin-treated animals.

Epigenetic and Transcriptional Remodeling

Beyond acute mTORC1 substrate suppression, chronic rapamycin treatment in aged organisms produces broad transcriptional remodeling that partially reverses aged gene expression patterns toward a youthful signature. mTORC1 drives the expression of ribosomal protein genes, translation factors, and genes encoding metabolic enzymes through TFEB’s inverse (cytoplasmic retention in the mTOR-active state) and through S6K1-mediated phosphorylation of chromatin-remodeling factors; rapamycin-induced mTOR inhibition reduces this anabolic gene expression program and increases expression of stress resistance, autophagy, and proteostasis genes. In the heart, rapamycin treatment of aged mice reverses the gene expression signature of cardiac aging, with particular normalization of contractile protein ratios and mitochondrial metabolic genes. Rapamycin also modulates expression of multiple microRNAs involved in aging and senescence biology, including miR-21 (pro-fibrotic and oncogenic) reduction and miR-29 (anti-fibrotic) induction, suggesting that the transcriptional remodeling extends beyond direct mTORC1 substrate regulation into broader epigenetic programming. The durability of these transcriptional changes after rapamycin discontinuation is not well characterized but is an active research area relevant to the question of whether longevity benefits persist after treatment cessation.

Clinical Evidence

Lifespan Extension in Mammalian Models

The ITP evidence for rapamycin lifespan extension is the most replicated and rigorously controlled pharmacological longevity dataset in mammals. Harrison et al. (Nature, 2009; PMID 19587680) demonstrated median lifespan extension of 9 percent in males and 14 percent in females at 14 ppm dietary rapamycin initiated at 600 days of age in UM-HET3 mice, across three independent sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center). The study used a genetically heterogeneous mouse line specifically designed to reduce genetic drift and increase translatability, and the identical result across three sites with different housing and husbandry conditions provides exceptional reproducibility. Subsequent ITP cohorts using encapsulated rapamycin at higher dietary concentrations produced larger lifespan extensions, with maximum lifespan (90th percentile survival) also significantly extended, distinguishing rapamycin from interventions that merely reduce early mortality without affecting the aging rate. The lifespan extension is accompanied by improvements in multiple health metrics in aged animals: Flynn et al. (Aging, 2013) showed reversal of established cardiac hypertrophy and improved diastolic function after 10 weeks of rapamycin in 22-month-old mice; Neff et al. showed improvements in tendon biomechanical properties; and multiple groups have demonstrated improved cognitive performance and reduced neuroinflammation in aged rapamycin-treated mice. The effect is not limited to mice: TOR pathway reduction extends lifespan in S. cerevisiae, C. elegans, and Drosophila, and Bjedov et al. (Cell Metab, 2010; PMID 20399148) showed up to 25 percent lifespan extension in Drosophila with dietary rapamycin across multiple genotypes, establishing evolutionary conservation spanning the animal kingdom.

Immunosenescence Reversal in Humans

The Mannick 2014 trial (Sci Transl Med; PMID 25294889) remains the highest-quality human evidence for mTOR inhibition in aging. In this randomized double-blind placebo-controlled trial of 218 adults aged 65 and older, RAD001 (everolimus) administered for 6 weeks before influenza vaccination improved the proportion of subjects achieving protective influenza antibody titers (seroconversion) by approximately 20 percent at all three dose levels tested (0.5 mg daily, 5 mg weekly, 20 mg weekly). The 0.5 mg daily dose also significantly reduced PD-1-positive exhausted CD4 and CD8 T-cells by 10 to 30 percent, a direct biomarker of immune rejuvenation, without producing grade 3 or 4 adverse events. A follow-up phase 2b trial (Mannick et al., 2018; PMID 30377497) in 264 adults 65 and older tested low-dose RAD001 alone or with the PI3K-delta inhibitor BEZ235 and confirmed the immune rejuvenation findings, with a significant reduction in the frequency of self-reported infections over the following year (adjusted hazard ratio 0.67, 95 percent CI 0.45 to 0.99) in the RAD001-treated groups. Together these trials establish proof-of-concept that sub-immunosuppressive mTOR inhibition rejuvenates specific hallmarks of aging immunity in humans, though the optimal compound, dose, and treatment duration for broader healthspan benefit remain under investigation.

Renal Allograft Rejection and Transplant Applications

Sirolimus was FDA-approved in 1999 based on its efficacy in renal transplant rejection prophylaxis. The Rapamune Global Study Group conducted a multinational randomized trial (MacDonald, N Engl J Med, 2001; PMID 11387448; n=719) comparing sirolimus 2 mg per day or 5 mg per day (with cyclosporine and corticosteroids) to azathioprine in low-to-moderate immunological risk renal transplant recipients. Both sirolimus doses produced rejection rates at 12 months (approximately 19 to 24 percent) comparable to azathioprine (approximately 32 percent), with better 3-year graft survival outcomes in the sirolimus group in post-hoc analyses. The mechanistically distinct mechanism from calcineurin inhibitors (mTORC1 suppression versus IL-2 transcription blockade) makes sirolimus an attractive calcineurin inhibitor-sparing option for patients with calcineurin inhibitor nephrotoxicity. Therapeutic drug monitoring is essential in transplant: target whole-blood trough concentrations are 4 to 12 ng/mL when combined with cyclosporine or 12 to 20 ng/mL in cyclosporine-free regimens, with concentrations above 20 to 25 ng/mL associated with dose-dependent thrombocytopenia and hyperlipidemia. The most clinically significant limitation in transplant is impaired wound healing, which has led to recommendations to delay sirolimus initiation until 3 months post-transplant and to suspend it perioperatively for any surgical procedure.

Tuberous Sclerosis Complex and Lymphangioleiomyomatosis

The approved oncological applications of rapamycin and rapalogs in TSC and LAM are the closest to a direct validation of the on-target mTOR inhibition mechanism in human disease. TSC is caused by heterozygous loss-of-function in TSC1 or TSC2, which leads to constitutive Rheb activation and mTORC1 hyperactivation driving hamartoma formation. Everolimus is FDA-approved for TSC-associated SEGA (Phase 3 EXIST-1: n=117; 35 percent of patients had significant tumor volume reduction versus 0 percent with placebo), renal angiomyolipoma (EXIST-2: n=118; 42 percent response rate versus 0 percent), and TSC-related partial-onset seizures (EXIST-3). Sirolimus was approved for LAM based on the MILES trial (McCormack et al., N Engl J Med, 2011; PMID 21410393; n=89) showing that sirolimus stabilized FEV1 decline (0 mL per year versus -134 mL per year decline with placebo), reduced serum VEGF-D, and improved quality-of-life scores, with effects reversing 12 months after discontinuation, indicating the need for continuous therapy. These TSC/LAM data establish that mTOR inhibition has durable clinical benefit in mTORC1-driven disease and that the effect is on-target and mechanism-driven rather than idiosyncratic.

Cancer Treatment via Rapalogs

The oncological evidence base for mTOR inhibition spans multiple tumor types but is characterized by cytostatic efficacy rather than the deep and durable responses seen with kinase inhibitors in oncogene-addicted tumors. Temsirolimus demonstrated overall survival benefit (10.9 versus 7.3 months) in poor-risk advanced RCC (Global ARCC trial; Hudes et al., N Engl J Med, 2007; PMID 17452506; n=626), the only rapalog trial to show overall survival rather than PFS benefit as the primary endpoint. Everolimus received approval for second-line RCC (RECORD-1: n=410; PFS 4.9 versus 1.9 months with placebo), pancreatic NET (RADIANT-3: n=410; PMID 21306237; PFS 11.0 versus 4.6 months), and breast cancer in combination with exemestane (BOLERO-2: n=724; PFS 10.6 versus 4.1 months). The primary limitation of rapalogs in oncology is the S6K1-IRS-1 feedback loop: mTORC1 inhibition de-represses IRS-1 by reducing S6K1-mediated IRS-1 Ser307 phosphorylation, allowing compensatory PI3K-AKT activation that counteracts the antiproliferative effect; this feedback motivates combinations with PI3K inhibitors, dual PI3K/mTOR inhibitors, and AKT inhibitors in ongoing clinical development.

Adverse Effects in Long-Term Trials

The adverse effect profile of rapamycin and rapalogs is well characterized from thousands of patients in transplant and oncology trials, and must be contextualized by dose and indication when applied to longevity use. Hyperlipidemia (hypertriglyceridemia and hypercholesterolemia) occurs in 45 to 57 percent of transplant patients at standard sirolimus doses and responds to statin and fibrate therapy; the severity correlates with trough concentrations and is substantially lower at the sub-immunosuppressive concentrations used in longevity protocols. Impaired wound healing is the most clinically disruptive adverse effect in surgical patients and mandates preoperative sirolimus discontinuation. Pneumonitis, though rare (2 to 11 percent in transplant series), is potentially life-threatening and requires prompt recognition and corticosteroid treatment, and patients should be educated to report new respiratory symptoms. Infections in transplant patients are multifactorial and driven by the full immunosuppressive regimen rather than sirolimus alone. Oral mucositis is the most common complaint in longevity cohort case series and is the most frequent reason for dose reduction. Thrombocytopenia and anemia occur at transplant doses but appear rare in case series of longevity dosing. Long-term safety data for the specific low-dose intermittent regimens used in longevity practice are not available from randomized controlled trials; the ongoing PEARL trial will provide the most rigorous safety characterization to date.

Longevity and Off-Label Evidence

Off-label rapamycin use for aging is estimated to involve tens of thousands of individuals globally as of 2026, based on case series publications, physician survey data, and internet community reports. The most systematic published case series is Kaeberlein’s 2023 report (Aging, 2023) describing 333 individuals (median age 62 years) using rapamycin for longevity purposes for a median of 1.6 years; the most common regimen was 5 to 6 mg weekly, and the adverse event profile was generally consistent with sub-immunosuppressive exposure: 28 percent of users reported at least one side effect, with mouth sores the most common (13 percent), followed by mild infections (10 percent) and GI effects (6 percent). No serious infectious complications or pneumonitis events were reported in that series, though publication bias toward favorable outcomes in self-selected cohorts must be acknowledged. The PEARL trial (NCT04488601), an academic randomized controlled trial testing rapamycin at 5 and 10 mg per week in community-dwelling adults aged 50 to 85 without immunocompromising conditions, is the highest-priority human data source expected to characterize the safety, dosing, and biological effects of longevity-dose rapamycin. The Dog Aging Project has conducted a randomized, double-blind, placebo-controlled trial of rapamycin in companion dogs (average age 10 years), representing a pharmacologically relevant intermediate mammalian model whose results have been reported and are informing design of human trials.

Dosing Guidance

For FDA-approved transplant indications: sirolimus 6 mg loading dose followed by 2 mg per day maintenance in renal transplant, adjusted to trough concentrations of 4 to 12 ng/mL (with cyclosporine) or 12 to 20 ng/mL (calcineurin inhibitor-free regimens). For LAM: 2 mg per day titrated to troughs of 5 to 15 ng/mL. For off-label longevity use: no regulatory-established dose exists; the most cited regimens in the literature are 1 to 6 mg weekly; the PEARL trial tests 5 and 10 mg weekly; doses below 1 mg per week or above 10 mg per week are less commonly used in published series. Dose selection in longevity practice is typically guided by tolerability (oral ulcers, lipid effects) and, when measured, whole-blood trough concentrations (target below 3 ng/mL on weekly dosing). Any individual starting rapamycin off-label should have a full medication reconciliation for CYP3A4 interactions, baseline labs, and a clinician monitoring plan; self-administration without medical oversight is not recommended given the interaction complexity and the nascent evidence base.

Rapamycin versus Continuous versus Intermittent Dosing

The key pharmacological debate in longevity rapamycin use is continuous low-dose versus weekly intermittent dosing. Continuous daily dosing at sub-transplant doses provides sustained mTORC1 inhibition but risks progressive mTORC2 inhibition (and the associated insulin resistance) as demonstrated by Lamming et al. (Science, 2012) and Sarbassov et al. (Molecular Cell, 2006). Weekly intermittent dosing provides peak mTORC1 inhibition on the 1 to 3 days of highest drug concentration, with predicted mTOR recovery during the latter part of the week based on the approximately 62-hour half-life; this strategy is hypothesized to preserve mTORC2 function and insulin sensitivity while still providing the longevity benefit. The animal data directly comparing continuous and intermittent dosing for longevity outcomes are limited; most ITP studies use continuous dietary administration, but the ITP results were achieved at dietary concentrations that produce average blood exposures lower than daily human transplant dosing. No randomized human trial has directly compared continuous and intermittent longevity protocols. Until such data exist, the mechanistic argument for intermittent dosing based on mTORC2 preservation is compelling and widely adopted, but should be recognized as hypothesis-driven rather than empirically established in humans.